PEX19 (Peroxisome Biogenesis Factor 19), also known as peroxin-19, encodes the master cytosolic chaperone responsible for recognizing, folding, and targeting peroxisomal membrane proteins (PMPs) to the peroxisome. Often described as the "taxi driver" of peroxisomal proteins, PEX19 binds newly synthesized PMPs in the cytosol, maintains them in a soluble state, and delivers them to the peroxisomal membrane receptor PEX3 for insertion[@gottlieb2005]. This essential function makes PEX19 indispensable for peroxisome biogenesis, and mutations in PEX19 cause severe peroxisome biogenesis disorders (PBDs) that result in profound developmental defects and early lethality.
Beyond its fundamental role in peroxisome assembly, PEX19 has been increasingly implicated in common neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, where peroxisomal dysfunction contributes to disease pathogenesis. The receptor's central position at the nexus of peroxisome formation makes it a critical node in cellular lipid metabolism, oxidative stress management, and neuroprotection[@matsuzaki2008].
| Property |
Value |
| Gene Symbol |
PEX19 |
| Full Name |
Peroxisome Biogenesis Factor 19 |
| Chromosomal Location |
1q23.2 |
| NCBI Gene ID |
5294 |
| OMIM ID |
603419 |
| Ensembl ID |
ENSG00000162755 |
| UniProt ID |
P40818 |
| Encoded Protein |
Peroxin-19 |
| Protein Family |
PEX proteins, peroxisomal import chaperones |
| Protein Length |
326 amino acids |
| Subcellular Location |
Cytosol (primary), peroxisomal membrane (transient) |
Peroxisomal membrane proteins (PMPs) follow a distinct import pathway from matrix proteins[@schrader2012]:
- Recognition: PEX19 binds PMPs in the cytosol
- Solubilization: Maintains PMPs in soluble form
- Targeting: Directs PMPs to peroxisomal membrane
- Docking: Transfers PMPs to PEX3
- Insertion: PMPs integrate into peroxisomal membrane
This pathway is distinct from the PEX5/PEX7-dependent matrix protein import.
| Feature |
PMP Import (PEX19) |
Matrix Import (PEX5/PEX7) |
| Cargo |
Membrane proteins |
Matrix enzymes |
| Receptor |
PEX19 (chaperone) |
PEX5/PEX7 (receptor) |
| Destination |
Membrane |
Matrix |
| Signal |
Multiple (PEX19-binding motifs) |
PTS1 (SKL), PTS2 |
| ATP requirement |
Yes (chaperone function) |
Yes |
¶ PEX19 Structure and Function
PEX19 is a cytosolic protein with multiple functional domains:
- N-terminal domain: PEX3 binding site
- Central region: PMP recognition and binding
- C-terminal domain: Dimerization and chaperone activity
PEX19 functions as a molecular chaperone[@kim2010]:
Recognition:
- Binds to hydrophobic regions of PMPs
- Recognizes diverse PMPs with different structures
- Prevents aggregation in cytosol
Solubilization:
- Maintains PMPs in soluble conformation
- Protects from proteasomal degradation
- Enables targeting to peroxisomes
Targeting:
- Directs PMPs to peroxisomal membrane
- Interacts with PEX3 receptor
- Facilitates membrane insertion
PEX19 functions as a dimer:
- Homodimer formation: Required for function
- PMP binding: Two sites per dimer
- PEX3 interaction: Dimer binds PEX3
PEX19 and peroxisomes are relevant to AD pathogenesis[@coe2015]:
Peroxisome Deficiency:
- PEX19 function critical for peroxisome numbers
- Reduced peroxisomes in AD brain
- Contributes to metabolic dysfunction
Lipid Metabolism:
- Peroxisomes handle very long-chain fatty acids
- PEX19 dysfunction reduces metabolic capacity
- Lipid accumulation in neurons
Oxidative Stress:
- Catalase import depends on peroxisome function
- Reduced H2O2 detoxification
- Increased oxidative damage
PEX19 connects to multiple aspects of PD:
Lipid Metabolism:
- Peroxisomal β-oxidation important for neuronal lipid homeostasis
- PEX19 dysfunction compounds metabolic deficits
- May affect dopaminergic neurons specifically
Oxidative Stress:
- Peroxisomal antioxidant capacity reduced
- Enhanced vulnerability to oxidative damage
- Contributes to neurodegeneration
PEX3 Connection:
- PEX19 delivers PEX3 to membrane
- PEX3 mutations also cause PBDs
- Shared pathway with PEX19
Peroxisome Population:
- PEX19 determines peroxisome abundance
- Reduced peroxisomes in neurodegeneration
- Compromised metabolic capacity
Cellular Stress:
- Unimported PMPs may accumulate
- Triggers cellular stress responses
- Contributes to cell death
| Protein |
Interaction Type |
Functional Consequence |
| PEX3 |
Direct binding |
PMP docking and insertion |
| PMPs |
Chaperone binding |
Solubilization and targeting |
| PEX10 |
Functional connection |
Ubiquitin ligase complex |
| PEX2 |
Functional connection |
Import machinery |
| PEX12 |
Functional connection |
Import machinery |
PEX19 binds diverse PMPs:
- PEX3: Most abundant peroxisomal membrane protein
- PEX10, PEX12, PEX13: Import machinery components
- ABC transporters: Peroxisomal membrane transporters
- PEX11: Peroxisome proliferation factor
PEX19 is widely expressed:
| Tissue |
Expression Level |
| Liver |
High |
| Kidney |
High |
| Brain |
High |
| Heart |
Moderate |
| Muscle |
Moderate |
In the brain, PEX19 shows region-specific expression:
| Brain Region |
Expression Level |
Relevance |
| Cerebral Cortex |
High |
Cognitive function |
| Hippocampus |
High |
Memory |
| Cerebellum |
Moderate |
Motor |
| Substantia Nigra |
Moderate |
PD relevance |
- Neurons: Essential for peroxisome maintenance
- Astrocytes: Metabolic support
- Oligodendrocytes: Myelin lipid synthesis
- Microglia: ROS metabolism
PEX19 mutations cause severe PBDs[@honsho2016]:
Clinical Features:
- Severe developmental delay
- Dysmorphic facial features
- Neurological impairment
- Hepatic dysfunction
- Early lethality (severe cases)
Phenotypes:
- Zellweger syndrome (most severe)
- Neonatal adrenoleukodystrophy (NALD)
- Charcot-Marie-Tooth disease variant (mild)
Interestingly, PEX19 mutations have been linked to a form of Charcot-Marie-Tooth disease:
- Peripheral neuropathy phenotype
- Milder than classical PBDs
- Highlights tissue-specific effects
PEX19 participates in multiple pathways:
- De novo formation: ER-derived pre-peroxisomal vesicles
- Growth and division: Existing peroxisome proliferation
- Import of PMPs: Maintaining peroxisome population
Pexophagy:
- Damaged peroxisomes removed by autophagy
- PEX19 function affects quality control
- Maintains functional peroxisome pool
Gene Therapy:
- Restoration of functional PEX19
- Viral vector delivery approaches
- Under development for PBDs
Small Molecules:
- Enhance peroxisome function
- Bypass import deficits
- Protect against metabolic dysfunction
Combination:
- Gene therapy plus metabolic support
- Antioxidant therapy for neurodegeneration
- BBB penetration: CNS drug delivery
- Mutation-specific: Different variants require different approaches
- Early intervention: Critical for severe phenotypes
Peroxisomes oxidize fatty acids:
- Very long-chain fatty acids (>C22)
- Branched-chain fatty acids
- Dicarboxylic acids
- Prostaglandins
PEX19 maintains this capacity through peroxisome formation.
Peroxisomes synthesize plasmalogens:
- Ether phospholipids
- Critical for myelin structure
- Affected in PBDs and AD
- How is PEX19 expression regulated in different tissues?
- Can PEX19 modulation benefit neurodegenerative disease?
- What determines tissue-specific phenotype in PEX19 mutations?
- PEX19-based therapeutics
- iPSC models of PEX19 deficiency
- Peroxisome-targeted drug development
- Gottlieb & Imanaga, PEX19: a cytosolic chaperone for peroxisomal membrane proteins (2005)
- Matsuzaki et al., PEX19: the peroxisomal import receptor (2008)
- Kim et al., PEX19 and peroxisome biogenesis (2010)
- Jansen et al., Peroxisomal matrix protein import (2011)
- Wiemer et al., The peroxisomal protein import machinery (2012)
- Schrader et al., Peroxisome biogenesis and the import of membrane proteins (2012)
- Agrawal et al., PEX19: an essential player in peroxisome biogenesis (2016)
- Fujiki et al., Peroxisome biogenesis and import (2012)
- Honsho et al., PEX19 mutations cause peroxisome biogenesis disorders (2016)
- Coe et al., Peroxisomes in Alzheimer's disease (2015)
- Terlecky et al., Peroxisomes and oxidative stress in neurodegeneration (2012)
- Kovacs et al., Peroxisome deficiency in aging and disease (2014)